The Patent Finder

Viatris Specialty LLC.

8 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
7
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 19, 2026
    The maintenance fee for Process for annealing amorphous atorvastatin (US 9,034,913) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
  • 1 fee due Jan 14, 2027
    The maintenance fee for Process for Preparing Chiral Compounds (US 9,079,877) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 5 terms have ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

PatentTitleStatus Expires Confidence
US 7,875,731Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-BETA, DELTA-DIHYDROXY-5-1-Methylethyl)-3-Phenyl-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-Heptanoic Acid
In force
 · High confidence
In forceHigh confidence
US 8,026,376Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoicacid calcium salt (2:1)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,939,675Process for forming amorphous atorvastatin
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,084,488Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,079,877Process for Preparing Chiral Compounds
In force
 · Medium confidence
In forceMedium confidence
US 8,642,783Process for preparing chiral compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,034,913Process for annealing amorphous atorvastatin
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,383,667Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
In force
Term ended Nov 9, 2026 · From the USPTO record
In forceTerm ended Nov 9, 2026From the USPTO record
Also on record, not counted in the 8: 21 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited